Neurizon Therapeutics Limited has released a press release.
PharmAust receives $354k R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4C - Quarterly Report & Shareholders Update
- Monepantel reformulation successfully improves dose & taste
- Epichem Awarded One Year Contract Extension from DNDi
- Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
- PharmAust Raises $1.873m via an Oversubscribed Placement
Later from Neurizon Therapeutics
- Appendix 4D and Half Yearly Report & Accounts
- PharmAust enters option to license agreement with Elanco
- Appendix 4C & Company Update
- Chief Executive Officer resigns
- MPL successfully reformulated for canine clinical trials
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics